Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968557 | 0.85 | TDP1 (0.42) | L3MBTL1CNR2ALDH1A1HPGD | |
| SCHEMBL268626 | 0.85 | TDP1 (0.42) | L3MBTL1CNR2ALDH1A1HPGD | |
| SCHEMBL270922 | 0.84 | HDAC3 (0.42) | HDAC4HDAC7HDAC5ALDH1A1CYP2D6 | |
| SCHEMBL923969 | 0.84 | CYP1A2 (0.46) | ALDH1A1CYP2C19CNR1HPGD | |
| SCHEMBL496445 | 0.84 | RAB9A (0.46) | L3MBTL1CNR2ALDH1A1 | |
| SCHEMBL496468 | 0.83 | KMT2A (0.50) | HDAC4HDAC7HDAC5CYP2D6HPGD | |
| SCHEMBL9692751 | 0.81 | FFAR2 (0.46) | BRD4HDAC4HDAC7HDAC5FFAR2 | |
| SCHEMBL4507146 | 0.81 | L3MBTL1 (0.50) | BRD4HDAC4HDAC7HDAC5FFAR2 | |
| SCHEMBL924713 | 0.81 | SLC6A3 (0.48) | SLC6A4SLC6A3ALDH1A1SLC6A2 | |
| SCHEMBL268686 | 0.81 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1CYP2C9CYP2C19HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188282-B1 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-01-23 | — | — | EP | disclosed |
| US-8106215-B2 | 3-aza-bicyclo[3.3.0]octane compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-31 | — | — | US | disclosed |
| US-20110263662-A1 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-27 | — | — | US | disclosed |
| EP-2164847-B1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-09-14 | — | — | EP | disclosed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| US-7994336-B2 | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100184808-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-22 | — | — | US | disclosed |
| EP-2188282-A2 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-05-26 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
| EP-2164847-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-03-24 | — | — | EP | disclosed |
| EP-2069332-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009022311-A2 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009004584-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008020405-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263662-A1 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, OXTR | BRD4 1308/4885HDAC4 1480/4885HDAC7 2502/4885 |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | BRD4 2372/4885HDAC4 1750/4885HDAC7 1947/4885 |
| US-20100184808-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | HCRTR2, HCRTR1, OXTR | BRD4 560/4885HDAC4 355/4885HDAC7 288/4885 |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | BRD4 224/4885HDAC4 392/4885HDAC7 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.